Religare Enterprises Ltd H1 Income Rises 19% to ₹4,717 Crore
Key highlights
- Religare Enterprises Ltd reported H1 FY27 consolidated total income of ₹4,717 crore, up 19% year-on-year.
- Religare Enterprises Ltd recorded a consolidated loss after tax of ₹145 crore in H1 FY27.
- Care Health reported H1 FY27 insurance revenue of ₹6,119 crore, up 29%, and gross written premium of ₹6,897 crore, up 35%.
- Religare Broking's Q2 FY27 total income rose 7% to ₹197 crore.
powered by IRIS

Religare Enterprises Ltd reported consolidated total income of about ₹4,717 crore for H1 FY27, a 19% year-on-year increase, but posted a consolidated loss after tax of ₹145 crore for the half year. The results underline the scale of growth in its insurance operations while the group remained loss-making on a consolidated basis.
Know Religare Enterprises inside out
Results, valuation, peers and who's buying, in one view.
What did Religare Enterprises Ltd report for H1 FY27?
Religare Enterprises Ltd said its consolidated total income rose 19% year-on-year to around ₹4,717 crore in the first half of FY27. The company reported a consolidated loss after tax of ₹145 crore for the same period during its earnings call held on November 13, 2026.
The group operates across financial services and insurance. Its financial-services businesses include Religare Broking, Religare Finvest and Religare Housing Development Finance Corporation. Its insurance business is Care Health Insurance, which the company described as India’s second-largest standalone health insurer.
The half-year outcome shows that income growth did not translate into consolidated profitability. Management did not provide a half-year consolidated expense figure in the material provided, though it disclosed a loss before tax of ₹128 crore for the September quarter.
How did the September quarter affect the half-year result?
REL reported total income of ₹2,390 crore and total expenses of ₹2,518 crore in Q2 FY27, resulting in a loss before tax of ₹128 crore. The quarterly expense level was therefore above reported income, contributing to the group’s loss-making position for the half year.
The Q2 earnings call followed the company’s Q1 FY27 update, when it had reported consolidated total income of around ₹2,358 crore and a negative profit before tax of ₹76.73 crore. In that quarter, the reported profit after tax was negative ₹46.9 crore, with management citing different reporting standards as a key factor.
REL’s standalone holding-company operations are also limited in scale relative to its consolidated businesses. In Q1, the non-operating core investment company reported income of ₹4.38 crore, expenses of ₹14 crore and a net loss of ₹9.62 crore. The consolidated performance is consequently shaped primarily by the operating subsidiaries.
Which businesses drove Religare Enterprises Ltd's income growth?
REL identified Care Health Insurance as the principal growth business within the group. Care Health’s insurance revenue for H1 FY27 stood at ₹6,119 crore, up 29%, according to the earnings call. Separately, the company reported gross written premium of ₹6,897 crore for Care Health, up 35%.
These are different insurance measures and should not be treated as directly interchangeable. The reported revenue figure reflects insurance revenue, while gross written premium measures premium written by the insurer. Both figures indicate growth in the insurance operation during the first half.
Religare Broking also reported growth. Its Q2 total income increased 7% year-on-year to ₹197 crore, supported by a 13% increase in brokerage income and more than 21% growth in interest income. Management said the client debit book increased by more than 50% in the quarter.
The Q1 broking update had similarly cited a 7% rise in total income to ₹99.5 crore, alongside 13% brokerage-income growth, 28% interest-income growth and a 78% increase in the client debit book. These figures suggest that interest income and the client funding book were important contributors alongside core brokerage revenue.
Got a follow-up? Ask IRIS
What do Care Health's underwriting figures show?
Care Health reported an H1 FY27 combined ratio of 100.5% under Ind AS, improving by 70 basis points from the comparable earlier period. A combined ratio brings together claims and operating expenses relative to premium-related income, making it a key indicator of insurance underwriting performance.
A ratio close to 100% means claims and expenses broadly absorb the relevant insurance income. The 70-basis-point improvement is therefore notable, but the disclosed ratio remained above 100%. REL also reported Care Health profit before tax of ₹392 crore under Ind AS, up 42% in H1 FY27.
The insurance unit’s growth and reported profit contrast with the parent group’s consolidated loss. This difference reflects the presence of other operations and the consolidated reporting framework. The call material does not provide enough detail to assign the entire group loss to any single subsidiary or business line.
What are the key plans and unresolved issues for REL investors?
REL outlined plans for Religare Finvest to reach disbursements of ₹1,500 crore to ₹1,700 crore in FY28. The call summary also referred to a planned ₹300 crore rights issue and to expected warrant inflows of ₹800 crore by March 2027, which were linked to the company’s reported solvency position of 1.55 times.
Management also referred to an objective of bringing Care Health’s combined ratio near 100% by March 2028. These are management plans and targets rather than reported financial outcomes. Their execution will depend on operating performance and the stated capital-related actions.
The call material noted that a proposed demerger did not have a disclosed timeline. It also highlighted uncertainty around distribution rules, while describing broking-market conditions in Q2 as subdued. These remain relevant operating and regulatory considerations alongside the reported income growth.
Conclusion
Religare Enterprises Ltd delivered 19% growth in consolidated H1 FY27 total income to ₹4,717 crore, led by expansion in Care Health Insurance and continued growth at Religare Broking. However, the group’s ₹145 crore consolidated loss after tax and Q2 loss before tax of ₹128 crore show that income growth has not yet resulted in consolidated profitability.
Investors will watch the planned ₹300 crore rights issue, the expected ₹800 crore warrant inflows by March 2027, and progress toward Religare Finvest’s FY28 disbursement target. Care Health’s path toward a combined ratio near 100% by March 2028 and any update on the demerger timeline will also be important disclosures.


